Contribution: Industrial Research Assistance Program – Contributions to Firms
Jenthera Therapeutics inc.
$98,270.00
In vivo proof of concept study of Nuc-Nab gene editing complex targeting the KRAS oncogene
EF 2021-22 · 2021-12-20
Résumé
Using a known oncogene as the target, this project will aim at generating a proof of concept in animal for a novel gene editing therapeutic platform. Using a proprietary targeting mechanism, prior to the proposed project, in vitro demonstrations with very encouraging results were obtained.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Montreal|Montréal, Quebec, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
701783482
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2021-12-20 | 2021-22 | $98,270.00 |
| 2 | 2021-12-20 | 2021-22 | $98,270.00 |
| 4 | 2021-12-20 | 2021-22 | $98,270.00 |
Tel que publié
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 70 days.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 70 jours.
Agreement End Date
2022-12-30
Agreement Number
983780
Agreement Start Date
2021-12-20
Agreement Title
In vivo proof of concept study of Nuc-Nab gene editing complex targeting the KRAS oncogene
Agreement Title (French)
Étude de preuve de concept in vivo du complexe d'édition de gènes Nuc-Nab ciblant l'oncogène KRAS
Agreement Type
Contribution
Agreement Value
$98,270.00
Amendment Date
2022-09-01
Amendment Number
4
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Using a known oncogene as the target, this project will aim at generating a proof of concept in animal for a novel gene editing therapeutic platform. Using a proprietary targeting mechanism, prior to the proposed project, in vitro demonstrations with very encouraging results were obtained.
Description (French)
En utilisant un oncogène connu comme cible, ce projet visera à générer une preuve de concept chez l'animal pour une nouvelle plateforme thérapeutique d'édition de gènes. En utilisant un mécanisme de ciblage propriétaire, des démonstrations in vitro avec des résultats très encourageants ont été obtenues avant le projet proposé.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mount Royal
Federal Riding (French)
Mont-Royal
Federal Riding Number
24052
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
701783482
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Jenthera Therapeutics inc.
Recipient Postal Code
H4W 1K7
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2021-2022-Q3-983780
